MacKenzie Realty Capital Reports Second Quarter FY 2025 Financial Results, Return to Positive FFO
ORINDA, Calif., Feb. 14, 2025 (GLOBE NEWSWIRE) -- MacKenzie Realty Capital, Inc. (Nasdaq: MKZR) ('MacKenzie' or the 'Company') today announced its financial results for the second quarter ended December 31, 2025.
Key Financial Highlights:Operating Results for the Three Months Ended December 31, 2024:
The Company had positive $2.8 million of funds from operations ('FFO') for the quarter, a return to positive FFO. The net loss of $4.5 million was offset by $2.2 million in depreciation expense and $5.1 million of impairment loss. Revenue for the quarter benefited by a $3.0 million early termination fee from the anchor tenant at MacKenzie Satellite Place.
Net revenues for three months ended December 31, 2024, were $8.0 million, an increase of 124% from $3.6 million in the same period of 2023.
Net operating income was $6.3 million, an of increase of 205%, from $2.1 million in the same period of 2023.
Net loss was $4.5 million, compared to a $1.6 million loss in the same period of 2023.
Paid a common stock quarterly dividend in the amount of $0.05 per share for the period ended December 31, 2024.
Total shareholder equity was $97.7 million.
Robert Dixon, President of MacKenzie, said 'We are gratified that our revenues continued to grow at a healthy pace, and that our operating expenses have declined significantly as both a percentage of our revenues as well as of our assets. We still have improvements to make, but the progress last quarter was significant.'
About MacKenzie Realty Capital, Inc. MacKenzie, founded in 2013, is a West Coast-focused REIT that intends to invest at least 80% of its total assets in real property, and up to a maximum of 20% of its total assets in illiquid real estate securities. We intend for the real property portfolio to be approximately 50% multifamily and 50% boutique class A office. The Company has paid a dividend every year since inception. The current portfolio includes interests in 4 multifamily properties and 8 office properties plus 2 multifamily developments.
For more information, please contact MacKenzie at (800) 854-8357. Please visit our website at: http://www.mackenzierealty.com
Forward-Looking StatementsThis press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, among others, our ability to remain financially healthy, and our expected future growth prospects. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements. In some cases, forward-looking statements can be identified by the use of forward-looking terms such as 'anticipate,' 'estimate,' 'believe,' 'continue,' 'could,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'should,' 'will,' 'expect,' 'objective,' 'projection,' 'forecast,' 'goal,' 'guidance,' 'outlook,' 'effort,' 'target,' 'trajectory,' 'focus,' 'work to,' 'attempt,' 'pursue,' or the negative of these terms or other comparable terms. However, the absence of these words does not mean that the statements are not forward-looking. These forward-looking statements are based on certain assumptions and analyses made by us in light of our experience and our perception of historical trends, current conditions and expected future developments, as well as other factors we believe are appropriate in the circumstances. For a further discussion of factors that could cause our future results, performance, or transactions to differ significantly from those expressed in any forward-looking statement, please see the section titled 'Risk Factors' in annual reports on Form 10-K and quarterly reports on Form 10-Q that we file with the Securities and Exchange Commission from time to time.
89 Davis Road, Suite 100 • Orinda, California 94563 • Toll-Free (800) 854-8357 • Local (925) 631-9100 • www.mackenzierealty.com
IR CONTACTAndrew Barwicki516-662-9461andrew@barwicki.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
16 minutes ago
- Business Wire
Alnylam Receives European Commission Approval for AMVUTTRA ® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the European Commission (EC) has granted approval for the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM) as an additional indication for its orphan RNAi therapeutic AMVUTTRA ® (vutrisiran). The approval broadens the indication for AMVUTTRA, which now becomes the first and only RNAi therapeutic approved by the EC for the treatment of the cardiomyopathy manifestations of ATTR amyloidosis and the polyneuropathy manifestations of hereditary transthyretin-mediated amyloidosis (hATTR) in adults. Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy Share 'Estimates show approximately 100,000 people are affected by ATTR amyloidosis across Europe, most with cardiomyopathy, so this approval marks a critical step toward addressing this underserved patient population,' said Pushkal Garg, M.D., Chief Medical Officer at Alnylam. 'AMVUTTRA is supported by a well-established efficacy and safety profile, with over 6,000 patient-years of global experience in the treatment of hATTR with polyneuropathy. By delivering rapid and sustained knockdown of TTR through convenient, quarterly dosing, it offers a clinically differentiated approach with the potential to transform outcomes for patients living with this debilitating and potentially fatal disease. We now look forward to securing access to AMVUTTRA for eligible patients across the EU as quickly as possible.' The EC decision is based on positive results from the pivotal HELIOS-B Phase 3 study – a randomized, double-blind, placebo-controlled, multicenter, global trial that enrolled a diverse group of patients reflective of the contemporary ATTR-CM population, including those receiving substantial concurrent use of available standard-of-care therapies such as tafamidis and SGLT2 inhibitors. AMVUTTRA met all 10 pre-specified primary and secondary endpoints across both the overall and monotherapy populations. These included statistically significant reductions in all-cause mortality and recurrent cardiovascular events, as well as significant improvements in functional capacity (6-minute walk test), health status and quality of life (Kansas City Cardiomyopathy Questionnaire), and heart failure symptoms and severity (NYHA class). In the overall population, AMVUTTRA achieved a 28% reduction in the primary composite of all-cause mortality and recurrent cardiovascular events as compared to placebo. Mortality in this population was significantly reduced by 36% through 42 months in a pre-specified secondary endpoint analysis which included up to 36 months of the double-blind period plus six months of open-label extension. In HELIOS-B, rates of adverse events (AEs), serious AEs, severe AEs and AEs leading to study drug discontinuation were similar between the AMVUTTRA and placebo arms. Adverse drug reactions of AMVUTTRA include injection site reactions and increase in blood alkaline phosphatase and alanine transaminase. Detailed results from the HELIOS-B study were published in The New England Journal of Medicine. 1 'The HELIOS-B findings provide compelling evidence to support the use of vutrisiran as a first-line treatment option for patients with ATTR-CM,' said Marianna Fontana, M.D., Ph.D., HELIOS-B investigator, Professor of Cardiology, University College London, National Amyloidosis Center, Royal Free Hospital, London. 'As a physician, it is a privilege to see the true impact on patients in the clinic. The trial enrolled a broad population reflective of real-world clinical practice, and that's what makes the results so meaningful. This is a milestone for patients, who now have a new treatment option that has the potential to significantly improve outcomes of this disease.' ATTR-CM is caused by the deposition of misfolded TTR fibrils, which drive progressive and irreversible cardiovascular damage and premature death. AMVUTTRA is an RNAi therapeutic that works upstream by delivering sustained knockdown of disease-causing TTR at its source. In the EU, it is administered as a subcutaneous injection once every three months, either by a healthcare professional, or self-administered by patients or their caregivers, offering flexibility in treatment delivery. 'Amyloidosis is a serious and progressive disease that significantly impacts not only patients' physical health, but also their quality of life and independence. I am thrilled by the news of a new therapy for people in the EU living with ATTR-CM who often face delayed diagnosis. Having a new treatment option available marks a welcome development for the amyloidosis community,' said Giovanni d'Alessio, President of the Amyloidosis Alliance. In May 2025, the European Medicines Agency's Committee for Orphan Medicinal Products (COMP) adopted a positive opinion on the maintenance of the EU Orphan Designation for AMVUTTRA in ATTR amyloidosis. AMVUTTRA was approved in March 2025 by the U.S. Food and Drug Administration (FDA) and the Brazilian Health Regulatory Agency (ANVISA) for the treatment of the cardiomyopathy of wild-type or hereditary ATTR amyloidosis in adults. Alnylam continues to pursue additional global submissions to bring vutrisiran to patients worldwide. Indications In the EU, AMVUTTRA ® (vutrisiran) is indicated for the treatment of: hereditary transthyretin amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy (hATTR-PN). wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM). Important Safety Information Reduced Serum Vitamin A Levels and Recommended Supplementation Vutrisiran treatment leads to a decrease in serum vitamin A levels. Supplementation of approximately, but not exceeding, 2500 IU to 3000 IU vitamin A per day is advised for patients taking vutrisiran. Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g., night blindness). Adverse Reactions Commonly reported adverse reactions with vutrisiran were injection site reactions and increase in blood alkaline phosphatase and alanine transaminase. For additional information about vutrisiran, please see the full Summary of Product Characteristics. About AMVUTTRA ® (vutrisiran) AMVUTTRA ® (vutrisiran) is an RNAi therapeutic that delivers rapid knockdown of variant and wild‑type transthyretin (TTR), addressing the underlying cause of transthyretin (ATTR) amyloidosis. Administered quarterly via subcutaneous injection, vutrisiran is approved and marketed in more than 15 countries for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults. It is also approved in the U.S. and Brazil for the treatment of wild-type or hereditary ATTR amyloidosis in adult patients with cardiomyopathy (ATTR-CM). In the EU, AMVUTTRA is administered once every three months, either by a healthcare professional or through self-administration by patients or their caregivers. About ATTR Transthyretin amyloidosis (ATTR) is an underdiagnosed, rapidly progressive, debilitating and fatal disease caused by misfolded transthyretin (TTR) proteins, which accumulate as amyloid deposits in various parts of the body, including the nerves, heart and gastrointestinal tract. Patients may present with polyneuropathy, cardiomyopathy or both manifestations of disease. There are two different forms of ATTR – hereditary ATTR (hATTR), which is caused by a TTR gene variant and affects approximately 50,000 people worldwide, and wild-type ATTR (wtATTR), which occurs without a TTR gene variant and impacts an estimated 200,000-300,000 people worldwide. 2-5 About RNAi RNAi (RNA interference) is a natural cellular process of gene silencing that represents one of the most promising and rapidly advancing frontiers in biology and drug development today. 6 Its discovery has been heralded as 'a major scientific breakthrough that happens once every decade or so,' and was recognized with the award of the 2006 Nobel Prize for Physiology or Medicine. 7 By harnessing the natural biological process of RNAi occurring in our cells, a new class of medicines known as RNAi therapeutics is now a reality. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam's RNAi therapeutic platform, function upstream of today's medicines by potently silencing messenger RNA (mRNA) – the genetic precursors that encode for disease-causing or disease pathway proteins – thus preventing them from being made. 6 This is a revolutionary approach with the potential to transform the care of patients with genetic and other diseases. About Alnylam Pharmaceuticals Alnylam (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding in 2002, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam has a deep pipeline of investigational medicines, including multiple product candidates that are in late-stage development. Alnylam is executing on its ' Alnylam P 5 x25 ' strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. Alnylam Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than historical statements of fact regarding Alnylam's expectations, beliefs, goals, plans or prospects including, without limitation, Alnylam's expectations regarding the safety and efficacy of AMVUTTRA for the treatment of ATTR-CM; the potential for AMVUTTRA to be used as a first-line treatment for ATTR-CM; the potential for AMVUTTRA to address the underserved ATTR-CM patient population and to improve outcomes for ATTR-CM patients; and Alnylam's ability to secure access to AMVUTTRA for eligible patients across the EU and the timing of such access should be considered forward-looking statements. Actual results and future plans may differ materially from those indicated by these forward-looking statements as a result of various important risks, uncertainties and other factors, including, without limitation, risks and uncertainties relating to: Alnylam's ability to successfully execute on its ' Alnylam P 5 x25 ' strategy; Alnylam's ability to successfully demonstrate the efficacy and safety of its product candidates; the pre-clinical and clinical results for Alnylam's product candidates; actions or advice of regulatory agencies and Alnylam's ability to obtain regulatory approval for its product candidates, as well as favorable pricing and reimbursement; successfully launching, marketing and selling Alnylam's approved products globally; and any delays, interruptions or failures in the manufacture and supply of Alnylam's product candidates or its marketed products; as well as those risks more fully discussed in the 'Risk Factors' filed with Alnylam's 2024 Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC), as may be updated from time to time in Alnylam's subsequent Quarterly Reports on Form 10-Q and in its other SEC filings. In addition, any forward-looking statements represent Alnylam's views only as of today and should not be relied upon as representing its views as of any subsequent date. Alnylam explicitly disclaims any obligation, except to the extent required by law, to update any forward-looking statements.
Business Wire
27 minutes ago
- Business Wire
ACI Worldwide Appoints Robert Leibrock as Chief Financial Officer
OMAHA, Neb.--(BUSINESS WIRE)-- ACI Worldwide (NASDAQ: ACIW), an original innovator in global payments technology, today announced the appointment of Robert ('Bobby') Leibrock as Chief Financial Officer (CFO), effective July 1, 2025. Mr. Leibrock succeeds Scott Behrens, who is retiring following an exemplary career spanning nearly two decades at ACI. Mr. Leibrock joins ACI from Red Hat, Inc., where he currently serves as Senior Vice President, Chief Operating Officer and CFO. Red Hat is the open hybrid cloud technology leader, supporting transformative IT innovation and AI applications. At Red Hat, Mr. Leibrock successfully guided global financial operations through significant growth and strategic transformation, including initiatives focused on advancing AI capabilities and investments. He previously held senior finance roles at IBM, where he was instrumental in driving meaningful revenue growth through his leadership of financial strategy, operational excellence, and profitability improvement initiatives. 'I am delighted to welcome Bobby to ACI,' said Thomas Warsop, President and CEO of ACI Worldwide. 'His extensive experience leading finance organizations in global, complex environments, particularly in cloud and SaaS-focused businesses, will be invaluable as we continue to execute our growth strategy. His strategic acumen and proven financial expertise position him well to drive our financial discipline and operational excellence.' Warsop continued, 'Scott has skillfully guided ACI's global financial strategies and activities since joining the company in 2007. He's been a strong, steady leader who effectively communicated ACI's financial story and served as a true partner in advancing our transformation into a dynamic and innovative growth company. We are fortunate to draw on Scott's considerable expertise during this transition and extend our deepest gratitude for his significant contributions. We wish him the very best in his well-deserved retirement." 'It has been the greatest privilege of my career to serve as ACI's CFO and lead our talented finance team,' Behrens said. 'Today, ACI is positioned to win, and our financial posture, strategic priorities, and operational execution remain unchanged, underscoring our commitment to continuity and delivering market-leading payment software solutions around the globe. I look forward to working with Bobby and the ACI leadership team for as long as needed to ensure a smooth and orderly transition.' 'I'm excited to join ACI Worldwide at such a pivotal moment in the evolution of payments and real-time technology,' said Leibrock. 'I look forward to partnering with Tom and the talented ACI team to scale innovation, strengthen financial performance, build on our industry leadership, and create lasting value for shareholders.' Company Reaffirms Full-Year 2025 Financial Guidance ACI Worldwide is reaffirming its Q2 and full year 2025 financial guidance as previously communicated, which represents 7% to 9% growth over 2024 on an FX-adjusted basis and is in line with the long-term growth targets ACI discussed at last year's Analyst Day. About Robert ('Bobby') Leibrock Mr. Leibrock joined Red Hat Inc. in 2022 as Senior Vice President and CFO. In this role, he oversaw all strategic finance functions to ensure operational excellence, including: accounting, finance and planning, tax, treasury, sales operations, audit, controls, data & analytics, procurement, and deal management. His role expanded to include the COO title in February 2025. Before joining Red Hat, he spent nearly 20 years at IBM in senior roles across the CFO and Software organizations. He was a pivotal member of the leadership team behind IBM's $34 billion acquisition of Red Hat and played a central role in driving the integration strategy and long-term value creation. Earlier in his IBM career, he held financial leadership positions spanning security and automation software, cloud platform, global technology services, and the mainframe business. Mr. Leibrock holds a bachelor's degree in business administration from University of Connecticut. About ACI Worldwide ACI Worldwide, an original innovator in global payments technology, delivers transformative software solutions that power intelligent payments orchestration in real time so banks, billers, and merchants can drive growth, while continuously modernizing their payment infrastructures, simply and securely. With 50 years of trusted payments expertise, we combine our global footprint with a local presence to offer enhanced payment experiences to stay ahead of constantly changing payment challenges and opportunities. © Copyright ACI Worldwide, Inc. 2025 ACI, ACI Worldwide, ACI Payments, Inc., ACI Pay, Speedpay and all ACI product/solution names are trademarks or registered trademarks of ACI Worldwide, Inc., or one of its subsidiaries, in the United States, other countries or both. Other parties' trademarks referenced are the property of their respective owners. FORWARD-LOOKING STATEMENTS This press release contains forward-looking statements based on current expectations that involve a number of risks and uncertainties. Generally, forward-looking statements do not relate strictly to historical or current facts and may include words or phrases such as 'believes,' 'will,' 'expects,' 'anticipates,' 'intends,' and words and phrases of similar impact. The forward-looking statements are made pursuant to safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, expectations regarding Q2 and full year 2025 financial guidance as previously communicated, which represents 7% to 9% growth over 2024 on an FX-adjusted basis and is in line with the long-term growth targets ACI discussed at last year's Analyst Day. All of the foregoing forward-looking statements are expressly qualified by the risk factors discussed in our filings with the Securities and Exchange Commission. Such factors include, but are not limited to, increased competition, business interruptions, cybersecurity incidents or failure of our information technology and communication systems, security breaches, our ability to attract and retain senior management personnel and skilled technical employees, future acquisitions, strategic partnerships and investments, divestitures and other restructuring activities, implementation and success of our strategy, impact if we convert some or all on-premise licenses from fixed-term to subscription model, anti-takeover provisions, exposure to credit or operating risks arising from certain payment funding methods, loss caused by theft or fraud, customer reluctance to switch to a new vendor, our ability to adequately defend our intellectual property, litigation, consent orders and other compliance agreements, our offshore software development activities, risks from operating internationally, including fluctuations in currency exchange rates, events in eastern Europe and the Middle East, adverse changes in the global economy, compliance of our products with applicable legislation, governmental regulations and industry standards, the complexity of our products and services and the risk that they may contain hidden defects, legal and business risks from artificial intelligence technology incorporated into our products, risks to our business from the use of artificial intelligence by our workforce, complex regulations applicable to our payments business, our compliance with privacy and cybersecurity regulations, compliance with requirements of the payment card networks and Nacha, exposure to unknown tax liabilities, changes in tax laws and regulations, consolidations and failures in the financial services industry, volatility in our stock price, demand for our products, failure to obtain renewals of customer contracts or to obtain such renewals on favorable terms, delay or cancellation of customer projects or inaccurate project completion estimates, changes in card association and debit network fees or products, impairment of our goodwill or intangible assets, the accuracy of management's backlog estimates, the cyclical nature of our revenue and earnings and the accuracy of forecasts due to the concentration of revenue-generating activity during the final weeks of each quarter, restrictions and other financial covenants in our debt agreements, our existing levels of debt, incurring additional debt, events outside of our control including natural disasters, wars, and outbreaks of disease, and revenues or revenue mix below expectations. For a detailed discussion of these risk factors, parties that are relying on the forward-looking statements should review our filings with the Securities and Exchange Commission, including our most recently filed Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q.
Forbes
27 minutes ago
- Forbes
Sell ADBE Stock Ahead Of Its Earnings?
CHONGQING, CHINA - JUNE 08: In this photo illustration, the logo of Adobe Inc. is displayed on a ... More smartphone screen, with the company's latest stock market chart visible in the background, reflecting investor sentiment and recent trading activity, on June 08, 2025, in Chongqing, China. (Photo Illustration by) Adobe (NASDAQ:ADBE) will announce its earnings on Thursday, June 12, 2025. Historically, the stock has shown negative reactions the day following earnings announcements. In the last five years, Adobe's stock has declined in 70% of cases, with a median drop of 7.4% and a maximum one-day loss of 16.8%. For traders focused on events, recognizing these historical trends can provide a competitive edge. You have two primary strategies to think about: Analysts anticipate Adobe's earnings to be $4.97 per share with sales of $5.8 billion. This reflects an increase from the same quarter last year, during which earnings were $4.48 per share on revenue of $5.31 billion. Although the company's subscription business has been thriving and is likely to boost sales this quarter, revenue growth in the generative AI sector has lagged behind expectations. It will be intriguing to observe how this trend evolves in the forthcoming report. Regarding the fundamentals, Adobe currently boasts a market capitalization of $180 billion. Over the past twelve months, the company has generated $22 billion in revenue, with $8.0 billion in operating profits and a net income of $6.8 billion. If you're looking for upside with lower volatility than individual stocks, the Trefis High Quality portfolio offers a viable alternative — it has outperformed the S&P 500 and achieved returns surpassing 91% since its inception. Also, check out – A Smart Bet On Adobe Stock Ahead Of Earnings? See earnings reaction history of all stocks Here are some insights on one-day (1D) post-earnings returns: Additional information about observed 5-Day (5D), and 21-Day (21D) returns post earnings is provided along with the statistics in the table below. ADBE 1D, 5D, and 21D Post Earnings Return A strategy with relatively lower risk (though not effective if the correlation is weak) is to investigate the correlation between short-term and medium-term returns post earnings, identify a pair with the highest correlation, and execute the suitable trade. For instance, if 1D and 5D display the highest correlation, a trader can take a 'long' position for the next 5 days if the 1D post-earnings return is positive. Below is some correlation data based on 5-year and 3-year (more recent) history. Note that the correlation 1D_5D pertains to the relationship between 1D post-earnings returns and following 5D returns. ADBE Correlation Between 1D, 5D and 21D Historical Returns Occasionally, the performance of peers can impact the post-earnings stock reaction. In fact, the price adjustment might start before the earnings are disclosed. Here is some historical data comparing the past post-earnings performance of Adobe stock with the stock performance of peers that reported earnings just prior to Adobe. For an equitable comparison, peer stock returns are also represented as post-earnings one-day (1D) returns. ADBE Correlation With Peer Earnings Discover more about Trefis RV strategy that has outperformed its all-cap stocks benchmark (a combination of all 3, the S&P 500, S&P mid-cap, and Russell 2000), providing substantial returns for investors. Additionally, if you are seeking upside with a more stable experience than an individual stock like Adobe, consider the High Quality portfolio, which has surpassed the S&P and achieved >91% returns since its inception.
